Neurol. praxi. 2024;25(1):62-65 | DOI: 10.36290/neu.2023.075
Ofatumumab in clinical practice
- Neurologická klinika 2. LF UK a FN Motol, Praha
The view of multiple sclerosis treatment is changing. The aim is to provide patients with highly effective treatment at an early stage of the disease. The number of patients on HET is growing, as is the range of drugs available, which now includes ofatumumab. Ofatumumab is a monoclonal antibody that targets CD20 lymphocytes. It has been shown to be highly and rapidly effective in suppressing inflammatory activity and, to some extent, disease progression without relapse. Although it is well tolerated and can be administered by the patient at home, it is still a selective immunosuppressive drug with potential side effects and thus the need for pharmacovigilance. The aim of this article is to alert neurologists to the practical aspects of treatment.
Keywords: ofatumumab, monoclonal antibodies against CD20 lymphocytes, high effective treatment, multiple sclerosis.
Received: November 15, 2023; Revised: November 26, 2023; Accepted: December 4, 2023; Prepublished online: December 4, 2023; Published: March 6, 2024 Show citation
References
- Bar‑Or A, Wiendl H, Montalban X, et al. Rapid and sustained B‑cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022;28(6):910-924. doi:10.1177/13524585211044479.
Go to original source... 
Go to PubMed... - Cohen J, Hauser S, Cross A, et al. Five‑Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis. Poster Presentation at the American Academy of Neurology (AAN). 2023, April 22-27, 2023. Go to original source...
- Gärtner J, Hauser SL, Bar‑Or A, et al. Efficacy and safety of ofatumumab in recently diagnosed, treatment‑naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Mult Scler. 2022;28(10):1562-1575. doi:10.1177/13524585221078825. Go to original source... Go to PubMed...
- Hauser SL, Bar‑Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557. doi:10.1056/NEJMoa1917246. Go to original source... Go to PubMed...
- Hauser SL, Zielman R, Das Gupta A, et al. Efficacy and safety of four‑year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open‑label extension. Mult Scler. 2023;29(11-12):1452-1464. doi:10.1177/13524585231195346. Go to original source... Go to PubMed...
- He A, Merkel B, Brown JWL, et al. Timing of high‑efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307-316. doi:10.1016/S1474-4422(20)30067-3. Go to original source... Go to PubMed...
- Marzo B, Vidal‑Jordana A, Castilló J, et al. Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti‑CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study [published online ahead of print, 2023 Sep 11]. J Neurol. 2023;10.1007/s00415-023-11973-y. doi:10.1007/s00415-023-11973-y. Go to original source... Go to PubMed...
- Oksbjerg NR, Nielsen SD, Blinkenberg M, Magyari M, Sellebjerg F. Anti‑CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Mult Scler Relat Disord. 2021;52:102988. doi:10.1016/j.msard.2021.102988. Go to original source... Go to PubMed...
- Otero‑Romero S, Lebrun‑Frénay C, Reyes S, et al. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Mult Scler. 2023;29(8):904-925. doi:10.1177/13524585231168043. Go to original source... Go to PubMed...
- Roohani P, Emiru T, Carpenter A, et al. Late onset multiple sclerosis: Is it really late onset? Mult Scler Relat Disord. 2014;3(4):444-449. doi:10.1016/j.msard.2014. 02. 004. Go to original source...
- Samjoo IA, Worthington E, Drudge C, et al. Comparison of ofatumumab and other disease‑modifying therapies for relapsing multiple sclerosis: a network meta‑analysis. J Comp Eff Res. 2020;9(18):1255-1274. doi:10.2217/cer-2020-0122. Go to original source... Go to PubMed...
- Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease‑modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273-279. doi:10.1136/practneurol-2015-001139. Go to original source... Go to PubMed...
- Tur C, Carbonell‑Mirabent P, Cobo‑Calvo Á, et al. Association of Early Progression Independent of Relapse Activity With Long‑term Disability After a First Demyelinating Event in Multiple Sclerosis. JAMA Neurol. 2023;80(2):151-160. Go to original source... Go to PubMed...
- Turner B, Cree BAC, Kappos L, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol. 2019;266(5):1182-1193. doi:10.1007/s00415-019-09248-6. Go to original source... Go to PubMed...
- Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS‑CMSC‑NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20(8):653-670. doi:10.1016/S1474-4422(21)00095-8. Go to original source... Go to PubMed...
- Yu H, Graham G, David OJ, et al. Population Pharmacokinetic‑B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis. CNS Drugs. 2022;36(3): 283-300. doi:10.1007/s40263-021-00895-w. Go to original source... Go to PubMed...